Synergistic antiallodynic interaction between gabapentin or carbamazepine and either benfotiamine or cyanocobalamin in neuropathic rats.
Anticonvulsants, including gabapentin and carbamazepine, have shown activity against several types of neuropathic pain; however, they have limiting side effects that may minimize their use. In this study the possible synergistic interaction between anticonvulsants and benfotiamine or cyanocobalamin on spinal nerve ligation-induced tactile allodynia was assessed. Oral administration of gabapentin (15-300 mg/kg), carbamazepine (10-300 mg/kg), benfotiamine (30-600 mg/kg) or cyanocobalamin (0.3-6.0 mg/kg) significantly reduced tactile allodynia in rats. Maximal antiallodynic effects were reached with gabapentin 300 mg/kg (approximately 70%), carbamazepine 300 mg/kg (approximately 66%), benfotiamine 600 mg/kg (approximately 51%) and cyanocobalamin 6 mg/kg (approximately 59%). At the highest tested doses, gabapentin, but not carbamazepine, benfotiamine or cyanocobalamin, significantly reduced motor coordination. Coadministration of gabapentin or carbamazepine with benfotiamine or cyanocobalamin in a fixed ratio markedly reduced spinal nerve ligation-induced tactile allodynia, showing a synergistic interaction between anticonvulsants and B vitamins. Data indicate that combinations of anticonvulsants with benfotiamine or cyanocobalamin are able to reduce tactile allodynia without affecting motor coordination in rats, and suggest the possible clinical use of these combinations in the treatment of neuropathic pain in humans.
Centro de Investigacion y de Estudios Avanzados, Unidad Monterrey, Apodaca, Nuevo Leon, Mexico.
Teresa
T
Mixcoatl-Zecuatl
Geovanna N
GN
Quinonez-Bastidas
Nadia L
NL
Caram-Salas
Monica
M
Ambriz-Tututi
Claudia I
CI
Araiza-Saldana
Hector I
HI
Rocha-Gonzalez
Roberto
R
Medina-Santillan
Gerardo
G
Reyes-Garcia
Vinicio
V
Granados-Soto
D000588:Amines / Q000494:pharmacology*; D000700:Analgesics; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D002220:Carbamazepine / Q000494:pharmacology*; D003509:Cyclohexanecarboxylic Acids / Q000494:pharmacology*; D004357:Drug Synergism; D005260:Female; D000077206:Gabapentin; D008026:Ligation; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D010147:Pain Measurement / Q000187:drug effects; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D010812:Physical Stimulation; D011597:Psychomotor Performance / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013127:Spinal Nerves / Q000473:pathology; D013831:Thiamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D014805:Vitamin B 12 / Q000494:pharmacology*; D014803:Vitamin B Complex / Q000494:pharmacology*; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology*
D000588:Amines; D000700:Analgesics; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D014803:Vitamin B Complex; D002220:Carbamazepine; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D014805:Vitamin B 12; D013831:Thiamine; C013835:benphothiamine